People: TEVA TA`ASIYOT FARMATSEVTIYOT BE`AM (TEVA.O)

TEVA.O on Nasdaq

57.10USD
9 Feb 2010
Price Change (% chg)

$0.18 (+0.32%)
Prev Close
$57.10
Open
--
Day's High
$57.59
Day's Low
$56.72
Volume
4,539,807
Avg. Vol
5,121,943
52-wk High
$59.62
52-wk Low
$41.70

view people for:

Summary

Name Age Since Current Position
Hurvitz, Eli 77 2002 Chairman of the Board
Yanai, Shlomo 57 2007 Chief Executive Officer, President
Frost, Phillip 73 2006 Vice Chairman of the Board
Desheh, Eyal 56 2008 Chief Financial Officer
Marth, William 54 2008 President and Chief Executive Officer of Teva North America, President and CEO of Teva USA
Abravanel, Isaac 54 2007 Corporate Vice President - Human Resources
Hurvitz, Chaim 48 2002 Group Vice President - International
Manor, Moshe 53 2009 Group Vice President - Global Branded Products
Shohet, Eli 51 2006 Vice President - Central & Eastern Europe
Yaari, Aharon 56 2006 Group Vice President - Global API division
Van Odijk, Gerard 52 2006 Group Vice President - Europe, President and CEO Teva Pharmaceuticals Europe B.V
Weiner, Ben-Zion 64 2006 Chief R&D Officer
Krinsky, Itzhak 56 2005 Corporate Vice President - Business Development
Karniel, Uzi 66 1978 Chief Legal Officer and Secretary
Suesskind, Dan 65 2010 Director
Heth, Meir 76 2002 Director
Cheshin, Ruth 72 1989 Director
Cohen, Abraham 73 1992 Director
Elstein, Amir 54 2009 Director
Many, Moshe 80 1987 Director
Shafir, Dov 77 1969 Director
Slonim, Ory 66 2008 Director
Meridor, Leora 61 2002 Director
Shamir, David 48 2004 Director
Abravanel, Roger 63 2007 Director
Propper, Dan 68 2007 Director
Kornberg, Roger 61 2007 Director
Nitzani, Joseph 63 2008 Director
» Insider Trading

Biographies

Name Description
Hurvitz, Eli Mr. Eli Hurvitz serves as Chairman of the Board of Teva Pharmaceutical Industries Limited (Teva) since April 22, 2002. Mr. Hurvitz has been determined by the Board to be a financial and accounting expert under Israeli law. Prior to becoming Chairman, he served as Teva’s President and Chief Executive Officer for over 25 years and has been employed at the Company for over 40 years. He serves as Chairman of the Board of The Israel Democracy Institute (IDI), Chairman of the Board of NeuroSurvival Technologies Ltd. (a private company) and is a Director of Vishay Intertechnology. He served as Chairman of the Israel Export Institute from 1974 through 1977 and as the President of the Israel Manufacturers Association from 1981 through 1986. Mr. Hurvitz was also Chairman of the Board at Bank Leumi Ltd. between 1986 and 1987, a Director of Koor Industries Ltd. from 1997 through 2004, and a member of the Belfer Center for Science and International Affairs at John F. Kennedy School of Government and at Harvard University from 2002 through 2005. He received his B.A. in Economics and Business Administration from The Hebrew University of Jerusalem in 1957.
Yanai, Shlomo Mr. Shlomo Yanai has been Chief Executive Officer and President in Teva Pharmaceutical Industries Limited since March 1, 2007. Prior to joining Teva, Mr. Yanai served as President and Chief Executive Officer of Makhteshim-Agan Industries Ltd. from 2003 until 2006. Before joining Makhteshim-Agan, Mr. Yanai served in the Israel Defense Forces (IDF) for 32 years, where he achieved the rank of Major General, and successively held two of the most senior positions within the IDF: Commanding Officer of the Southern Command and Head of the Division of Strategic Planning. Mr. Yanai was the Head of the Israeli security delegation to the peace talks at Camp David, Shepherdstown and Wye River. Mr. Yanai is Board Member of Lycord Natural Products Industries. He was also Board Member of Bank Leumi Le-Israel Ltd. from 2004 until 2007. Mr. Yanai is Member of the International Advisory Board of the M.B.A. program of Ben-Gurion University and an Honorary Member of the Board of the Herzliya Interdisciplinary Center’s Institute for Policy and Strategy. Mr. Yanai has received numerous awards, among them the Israel Defense Forces Distinguished Service Medal in 1973, the Max Perlman Award for Excellence in Global Business Management in 2005 and the Dun & Bradstreet Leadership Excellence Award in 2006. Mr. Yanai received a B.A. in Political Science and Economics from Tel Aviv University and an M.P.A. in National Resources Management from George Washington University, and is a graduate of the Advanced Management Program of the Harvard Business School.
Frost, Phillip Dr. Phillip Frost has served as Vice Chairman of the Board of Teva Pharmaceutical Industries Limited (Teva) since the completion of the Ivax acquisition in January 2006. He was also President of IVAX from 1991 until 1995. Dr. Frost presently is the Chairman of the Board and CEO of OPKO Health, Inc., a specialty pharmaceutical company, and Chairman of the Board of Ladenburg Thalmann Financial Services. Dr. Frost is a director of Northrop Grumman Corporation, Continucare Corporation Inc. and Modigene Inc. Within the past five years, Dr. Frost has also served as a director of Protalix BioTherapeutics, Inc., Castle Brands, Inc. and Cellular Technical Services, as Chairman of IVAX Diagnostics, Inc. and as co-Vice Chairman of the Board of Governors of the American Stock Exchange. He is a life member, and former Chairman, of the Board of Trustees of the University of Miami, a member of the Board of Trustees of The Scripps Research Institute and a member of the Board of Regents of the Smithsonian Institution. Dr. Frost received a B.A. in French literature from the University of Pennsylvania in 1957 and an M.D. from the Albert Einstein College of Medicine in 1961.
Desheh, Eyal Mr. Eyal Desheh serves as Chief Financial Officer at Teva Pharmaceutical Industries Limited (Teva) since July 2008. From 2000 until 2008, he was Executive Vice President and Chief Financial Officer of Check Point Software Technologies Ltd. Prior to joining Check Point, Mr. Desheh served as Chief Financial Officer of Scitex Corporation Ltd. Before joining Scitex, he held a number of finance management and business development roles at Teva, including, from 1989 to 1995, the position of Deputy CFO. Mr. Desheh holds a bachelor’s degree in Economics and an MBA in Finance, both from The Hebrew University of Jerusalem.
Marth, William Mr. William S. Marth has served as President and Chief Executive Officer of Teva North America since January 21, 2008 and as President and Chief Executive Officer of Teva USA since January 2005. He was previously Executive Vice President of Teva USA from January 2002 to January 2005. From July 1999 to January 2002, he was Vice President of Sales and Marketing for Teva USA. Prior to joining Teva USA, he held various positions with the Apothecon division of Bristol-Myers Squibb. On February 2008, Mr. Marth was elected Chairman of the Generic Pharmaceutical Association where he is also a member of the executive committee. Mr. Marth received his B.Sc. in pharmacy from the University of Illinois in 1977 and his M.B.A. in 1989 from the Keller Graduate School of Management in Chicago, Illinois. Mr. Marth serves on various boards and committees, including the executive committee of the Generic Pharmaceutical Association.
Abravanel, Isaac Mr. Isaac Abravanel was appointed Corporate Vice President, Human Resources at Teva Pharmaceutical Industries Limited (Teva) on September 16, 2007. From 2005 to 2007, he was Deputy CEO of Bezeq Israel Telecommunications Co. Ltd., responsible for operations, the business sector, the private sector, and human resources, and from 2001 to 2005, was the Senior VP of Operations & Customer Service at Pelephone Communications Ltd. From 1998 to 2000, he held the position of Executive Director of Israel’s Association of Chambers of Commerce. Mr. Abravanel retired from the Israeli Defense Force (IDF) in 1998 after serving as head of the Planning Division of the Human Resources Branch of the IDF. Mr. Abravanel holds a B.A. and an M.A. in political science from Haifa University.
Hurvitz, Chaim Mr. Chaim Hurvitz has served as Group Vice President, International at Teva Pharmaceutical Industries Limited (Teva) since April 2002. He was Vice President, Israeli Pharmaceutical Sales from May 1999 until April 2002. Mr. Hurvitz was the President and CEO of Teva Pharmaceuticals Europe, B.V. and was Vice President, European Pharmaceutical Sales from 1995 to 1999. From 1993 to 1994, he served as the General Manager of Teva’s European Office in The Netherlands and from 1990 to 1993 as the Head of the Pharmaceutical and OTC departments of Abic Ltd., a Teva subsidiary. Mr. Chaim Hurvitz received his B.A. in Political Science and Economics from Tel Aviv University in 1985.
Manor, Moshe Mr. Moshe Manor became Group Vice President, Global Branded Products at Teva Pharmaceutical Industries Limited (Teva) in January 2009 after serving as Group Vice President, Global Innovative Resources since January 2006. Mr. Manor was Vice President, Global Products Division from 2002 until January 2006. Previously, he was Vice President of Strategic Product Planning from 2000 to 2002 and Vice President Israel Pharmaceutical Sales from 1995 to 2000. He was the General Manager of Teva-labeled products in Israel from 1993 to 1994 and Marketing Director of the Israeli Pharmaceutical Division from 1989 to 1993. He received his B.A. in economics from the Hebrew University of Jerusalem in 1982 and his M.B.A. from Tel Aviv University in 1985.
Shohet, Eli Mr. Eli Shohet serves as Vice President, Central & Eastern Europe at Teva pharmaceutical Industries Limited (Teva) since January 2006, Mr. Shohet joined the newly created Office of the CEO and assumed the role of Chief Integration Officer (Ivax). From 1999 until 2006, he was Vice President, Business Development. He previously served as Chief Economist and assistant to Teva’s CEO from 1989 to 1993, President of Plantex U.S.A. from 1993 to 1996 and Director of Business Development for Teva’s API division from 1996 to 1999. Eli Shohet received his B.A. in economics from Bar-Ilan University in 1986.
Yaari, Aharon Mr. Aharon (Arik) Yaari has served as Group Vice President, Global API Division at Teva Pharmaceutical Industries Limited (Teva) since January 2006. Mr. Yaari was previously Vice President for the Global API Division from 2002 until January 2006. Mr. Yaari joined Teva in 1981 and among various assignments at Teva he served as Vice President, Marketing and Sales of Teva API Division from 1999 to 2002 and President of Plantex USA from 1996 to 1999. Aharon Yaari received his B.A. and M.A. in economics from The Hebrew University of Jerusalem in 1981 and 1988, respectively.
Van Odijk, Gerard Dr. Gerard W.M. Van Odijk joined Teva Pharmaceutical Industries Limited (Teva) as Group Vice President, Europe and President and CEO of Teva Pharmaceutical Europe B.V. in January 2006. Over the previous 18 years, he held a variety of senior positions in Europe at Glaxo, GlaxoWellcome and GlaxoSmithKline and served in commercial and general management positions in France, the United Kingdom and The Netherlands. Prior to joining Teva, Dr. Van Odijk was Senior Vice President and Area Director of GlaxoSmithKline Northern Europe. He received his M.D. from the State University of Utrecht in 1987.
Weiner, Ben-Zion Dr. Ben-Zion Weiner has been with Teva Pharmaceutical Industries Limited (Teva) since 1975. In January 2006, Dr. Weiner became Chief R&D Officer. Dr. Weiner was Vice President, Global Products from April 2002 until January 2006, and Vice President, Research and Development from 1986 to 2002. In 1975, Dr. Weiner received a Ph.D. in chemistry from the Hebrew University, where he also received B.Sc. and M.Sc. degrees. He conducted his post-doctorate research at Schering-Plough Corporation in the United States. He was granted the Rothschild Prize for Innovation/Export twice, in 1989 for the development of Alpha D3 for dialysis and osteoporosis patients and in 1999 for the development of Copaxone for multiple sclerosis.
Krinsky, Itzhak Prof. Itzhak Krinsky joined Teva Pharmaceutical Industries Limited (Teva) as Corporate Vice President, Business Development in May 2005. Prior to joining Teva, Prof. Krinsky was a Managing Director at the Silverfern Group, Inc., from January 2003 until February 2005 and managing Director from July 2001 through December 2002. Dr. Krinsky worked at I. Krinsky, a financial and investment consulting company in New York City. From January 1998 until May 2001 he was a senior strategist with the Investment Banking Research and Strategy Group of Bankers Trust (the predecessor of Deutsche Bank Securities), later he was promoted to Managing Director in the Acquisition and Corporate Advisory Group of Deutsche Bank Securities in New York. Prof. Krinsky’s academic career includes, Professor of Finance & Business Economics at Michael G. DeGroote School of Business, and McMaster University, Canada. He is also a visiting professor at number of universities globally. Prof. Krinsky has several publications in academic journals. He is currently a member of the boards of Can-fite Biopharma Ltd. and Advanced Vision Technology (A.V.T.) Ltd. Prof. Itzhak Krinsky received his B.A. and M.A. in economics from Tel Aviv University in 1976 and 1978, respectively, and his Ph.D. in economics from McMaster University in 1983.
Karniel, Uzi Mr. Uzi Karniel has served as Chief Legal Officer of Teva Pharmaseutical Industries Limited (Teva) since 1971 and as Teva’s Corporate Secretary since 1978. He received his LL.B from The Hebrew University in 1969. He is a member of the Executive Committee of the Israeli Association of Publicly Traded Companies.
Suesskind, Dan Dan S. Suesskind serves as Director for Teva Pharmaceutical Industries since January 5, 2010. Previously, he has been with the Company since 1977 and has been Chief Financial Officer from 1978 to 2008. From 1970 until 1976, he was a consultant and securities analyst with International Consultants Ltd. He served as a Director of Teva until 2001. Mr. Suesskind was also a Director of Lanoptics Ltd. until 1998. He was also a Director of ESC Medical Systems Ltd. until 1999 and a Director at First International Bank until 2003. Mr. Suesskind is currently a Member of the Board of Migdal Insurance Company Ltd., Ness Technologies Inc. and Syneron Medical Ltd., and a Member of the Investment Advisory Committee of the Jerusalem Foundation. Mr. Suesskind is a Member of the Board of Trustees at the Hebrew University. He is one of the founders and a Member of the steering committee of the Israeli Forum of Chief Financial Officers. Dan S. Suesskind received his B.A. in economics and political science from the Hebrew University in 1965 and an M.B.A. from the University of Massachusetts in 1969.
Heth, Meir Prof. Meir Heth serves on Teva Pharmaceutical Industries Limited's (Teva) Board since 1977 and served as Chairman of the Board from 1994 to 2002. During his service at Teva, Prof. Heth served as Chairman of the Executive Committee for an extended period. He was designated as the financial expert on Teva’s audit committee, for the purposes of SEC regulations and as financial and accounting expert under Israeli law. Prof. Heth has served as Chairman of the Board of Bank Leumi Ltd. and as Chairman of Bank Leumi Trust Company of New York from 1987 to 1988. From 1978 to 1986, Prof. Heth was Chairman of the Tel Aviv Stock Exchange. Prof. Heth was employed at The Bank of Israel from 1962, where he held various positions, including Senior Economist until 1968, Supervisor of Banks from 1969 to 1975 and Senior Advisor to the Governor from 1975 to 1977. Meir Heth is a Professor at the Law School of the College of Management.
Cheshin, Ruth Ms. Ruth Cheshin serves as a Member of the Board of Directors at Teva Pharmaceutical Industries Limited (Teva) since 1989. She is also the President of the Jerusalem Foundation, a multinational organization which raises funds around the world for the creation of social, educational and cultural projects for all the citizens of Jerusalem.
Cohen, Abraham Mr. Abraham E. Cohen serves as a Member of the Board of Directors at Teva Pharmaceutical Industries since 1992. In the years 1977 to 1988 he was the President of the Merck Sharp & Dohme International Division. Since his retirement in January 1992, Mr. Cohen has been active as an international business consultant. He is presently a Director at several companies including, Akzo Novel NV., Chugai Pharmaceutical Co. U.S.A., Neurobiological Technologies, Inc. and Vasomedical, Inc.
Elstein, Amir Mr. Amir Elstein rejoined Teva Pharmaseutical Industries Limited (Teva)'s Board of Directors in January 2009. From 2004 to 2008, Mr. Elstein was a member of Teva’s senior management, where most recently he held the position of Executive Vice President, Global Pharmaceutical Resources. From 1995 to 2004, Mr. Elstein served on the Company’s board of directors. Prior to joining Teva in 2004, Mr. Elstein held a number of executive positions at Intel Corporation, most recently as General Manager of Intel Electronics Ltd., an Israeli subsidiary of Intel Corporation. Mr. Elstein serves as Chairman of the Board of Tower Semiconductor Ltd, as a director of Israel Corporation Ltd. and as Chairman of the Board of Governors of the Jerusalem College of Engineering. Mr. Elstein also serves as a member of the board in a variety of academic, scientific, educational, social and cultural institutes. Mr. Elstein holds a B.Sc. in Physics and Mathematics from The Hebrew University of Jerusalem, an M.Sc. in Solid State Physics from the Department of Applied Physics of The Hebrew University of Jerusalem and a diploma of Senior Business Management from The Hebrew University of Jerusalem.
Many, Moshe Prof. Moshe Many serves as Director of Teva Pharmaceutical Industries Limited (Teva) since 1987, and has been President of the Ashqelon Academic College since January 2002. Prof. Many previously served as the President of the Tisom International School of Management. He is a former President of Tel Aviv University, former Medical Director of the Ramat Marpeh Hospital and former Deputy Chairman of Maccabi Health Care Fund. Prof. Many has been a Department Head at Tel Hashomer Hospital since 1976. He has served as a Director at Elbit Medical Imaging since 1997 and at Israel Laser Industries from 1994 to 1998. Prof. Moshe Many received his M.D. from Geneva University in 1952 and his Ph.D. in surgery from Tufts University in 1969.
Shafir, Dov Mr. Dov Shafir serves as a Director at Teva Pharmaceutical Industries Limited (Teva) since 1969. He served in the Israeli Navy for 27 years, retiring in 1975 with the rank of Captain. He served as Chairman of the Executive Committee of Teva’s Board of Directors from 1992 until 2002. Mr. Shafir served as a director of Am-Shav Technological Innovation Center from 2004 until 2007. He has been a director of Ofer Technologies Ltd. since 1996 and as director of BSD Harvest Ukraine Ltd. since 2008. Mr. Shafir graduated from the Ecole Superieure de Guerre Naval in Paris.
Slonim, Ory Mr. Ory Slonim rejoined Teva Pharmaseutical Industries Limited's (Teva) Board in June 2008. Mr. Slonim is an attorney who has been in private practice since 1970 and previously served on Teva’s Board from 1998 to 2003 as a statutory independent director. Between 1987 and 2007, Mr. Slonim was a director at Migdal Insurance Company Ltd., serving as Deputy Chairman from 2000 until 2007 and as Chairman of the company’s audit committee from 2001 until 2007. He presently serves as a director and Chairman of the audit committee of U. Dori Engineering Works Corp. Ltd., director and Chairman of the audit committee of Oil Refineries Ltd. and as Vice Chairman of Harel Insurance Investments & Financial Services Ltd. From 1989 to 2006, Mr. Slonim served as a Special Consultant to the Minister of Defense. Since 2006, Mr. Slonim has served as Chairman of Variety Club in Israel, where he was President from 1994 to 2007. Mr. Slonim received an LL.B degree from the Hebrew University in 1968.
Meridor, Leora Dr. Leora (Rubin) Meridor has been a Director of Teva Pharmaceutical Industries Limited (Teva) since December 2002. She is a Business and Financial consultant and served as the Chairman of the Board of Bezeq International Ltd. and Walla Communications Ltd. from 2001 to 2005, and of Hapoalim Capital Markets in 2001-2004. From 1996 to 2000, she was Senior Vice President and Head of the Credit and Risk Management Division of the First International Bank of Israel. Between 1983 and 1996, Dr. Meridor held various positions in the Bank of Israel, the last of which was Head of the Research Department. Dr. Meridor has had various teaching positions at the Hebrew University and holds a Bachelors degree in mathematics and physics, a Master’s degree in mathematics and a Ph.D. in economics from The Hebrew University of Jerusalem. She serves on several Boards of Directors (NICE Systems Ltd., Gilat Satellite Networks Ltd., Isrotel Ltd., GEJ Yizum Ltd. and Weizmann Institute of Science) and qualifies as a statutory Independent Director under Israeli law.
Shamir, David Mr. David Shamir was appointed Director at Teva Pharmaseutical Industries Limited (Teva) in 2004. Mr. Shamir has served as the General Manager of Texas Instruments Israel Ltd. since 2001. From 1986 to 2001, he served in several Research and Development, and management positions in Motorola Semiconductor Israel Ltd. David Shamir received his B.Sc. in Computer Engineering from the Technion, Israel Institute of Technology in 1986.
Abravanel, Roger Mr. Roger Abravanel joined Teva Pharmaceutical Indusries Limited's Board in January 2007, following a career in business consulting at McKinsey & Company. Mr. Abravanel joined McKinsey in 1972 and served as a Principal since 1979, a Director since 1984 and held many positions in industry practice groups including the specialty chemicals/pharmaceuticals practice. He retired from McKinsey in June 2006. Mr. Abravanel currently serves as an advisor to several public and private Italian institutions, including the Association of Business Leaders and the Italian government. Mr. Abravanel has served as a member of the Supervisory Board of Teva Pharmaceuticals Europe B.V., a subsidiary of Teva, since June 2006 and serves as a member of the Board of Directors of Luxottica Group S.p.A., Valentino Fashion Group S.p.A., Hugo Boss AG, Marazzi Group S.p.A., Banca Nazionale del Lavoro, a subsidiary of BNP Paribas, and the Italian Institute of Technology. Mr. Abravanel graduated with a bachelor's degree in chemical engineering at the Politecnic University in Milan in 1968 and received an M.B.A. from INSEAD in 1972.
Propper, Dan Mr. Dan Propper serves as Director at Teva Pharmaceutical Industries Limited since 2007. He has been Chairman of the Board of Osem Investments Ltd., an Israeli manufacturer of food products. Mr. Propper served as Chief Executive Officer of Osem for 25 years until April 2006. In addition to his role at Osem, from 1993 until 1999, Mr. Propper served as President of the Manufacturers Association of Israel, an independent umbrella organization representing industrial enterprises in Israel, and as Chairman of the Federation of Economic Organizations in Israel. Mr. Propper has received awards for his contributions to the Israeli industry and economy, including an honorary Doctorate from the Technion - Israel Institute of Technology in 1999. Mr. Propper serves as a member of the boards of CheckPoint Software Technologies Ltd., First International Bank of Israel, Delta Galil Industries Ltd. and a number of private companies. Mr. Propper is also Member of the board of trustees of the Technion and Ben-Gurion University and Member of the executive committees of the Weizmann Institute of Science and Tel Aviv University. Mr. Propper earned a B.S. summa cum laude in Chemical Engineering and Food Technology from the Technion Israel Institute of Technology.
Kornberg, Roger Prof. Roger D. Kornberg was appointed Director at Teva Pharmaceutical Industries Limited in 2007. He is the Winzer Professor in Medicine in the Department of Structural Biology at Stanford University, where he has been Professor since 1978. Prior to joining Stanford, he served as Professor at Harvard Medical School. Prof. Kornberg received a B.A. degree from Harvard in 1967 and a Ph.D. degree in Chemistry from Stanford in 1972. He has received many awards, including the Welch Prize (2001), the Leopold Mayer Prize (2002) and the Nobel Prize in Chemistry (unshared, 2006). He is a recipient of honorary degrees from universities in Europe and Israel, including the Hebrew University, where he is Visiting Professor. He is Member of the United States National Academy of Sciences and an Honorary Member of other academies and professional societies in the United States, Europe, and Japan.
Nitzani, Joseph Mr. Joseph Nitzani serves as Director at Teva Pharmaceutical Industries Limited since September 2008. He has served as Chairman of the Board of Hadassah Medical Center since June 2008. He has served as a Director of Hadassah Medical Center since 1996 and of Adanim Mortgage Bank Ltd. since 2006. Between 2001 and 2007, Mr. Nitzani held various positions at Mizrahi-Tefachot Bank Ltd., including Vice President, Head of Capital Markets, Client Assets and Private Banking Divisions. Mr. Nitzani also served as a Director of Tefachot Israeli Mortgage Bank Ltd. from 2003 to 2005. Previously, he served as Managing Director of The Government Companies Authority from 1991 to 1995 and of The Tel-Aviv Stock Exchange from 1983 to 1991. Mr. Nitzani received his BA in economics from Bar-Ilan University in 1971 and his MBA from Tel Aviv University in 1974. Mr. Nitzani qualifies as a statutory Independent Director under Israeli law.

Insider Trading

» Full list on Insider Trading
view people for: